July 19, 2023
FDA: Class I recall of Quidel Triage Cardiac Panels
Editor's Note
The Food and Drug Administration (FDA), on July 17, identified the recall by Quidel Cardiovascular Inc of its Quidel Triage Cardiac Panels as Class I, the most serious.
The recall was initiated because of reports of inaccurate tests showing lower than expected troponin levels in samples. A falsely low or negative troponin level may cause a delayed or missed diagnosis of myocardial infarction.
The company reports 41 complaints, no injuries, and no deaths related to this issue.
Distribution dates: Beginning November 1, 2022.
Free Daily News
- Healthcare employment up in November
- Nonprofit hospitals face ongoing struggles in 2024
- ASCs lock in higher Medicare, Medicaid payment rate
- HHS releases concept paper on cybersecurity for healthcare sector
- Study examines infection precautions during pandemic based on healthcare roles
- Postoperative opioid prescriptions falling, but more improvement needed
- New protein calculation uncovers which organs are aging at an accelerated pace
- Researchers are calling for better tracking of chronic diseases
- New Joint Commission certification addresses secondary use of data
- New wearable device system could aid in remote medical monitoring
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging